US FDA, EMEA look to harmonise postmarketing surveillance

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2007年 / 1152卷 / 1期

关键词：

Public Health; European Commission; Risk Management; Regulatory Agency; Information Sharing;

D O I：

10.2165/00128415-200711520-00003

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[21] EMEA, FDA collaboration moves forward
Reactions Weekly, 2008, 1208 (1) : 2 - 2
[22] FDA and EMEA pool scientific advice
Alla Katsnelson
Nature Biotechnology, 2004, 22 : 1490 - 1491
[23] FDA and EMEA pool scientific advice
Katsnelson, A
NATURE BIOTECHNOLOGY, 2004, 22 (12) : 1490 - 1491
[24] The US FDA is to review postmarketing reports of serious bleeding associated with dabigatran etexilate
Reactions Weekly, 2011, 1382 (1) : 5 - 5
[25] SHOULD THE FDA EMULATE EUROPE EMEA
WARD, M
BIO-TECHNOLOGY, 1995, 13 (07): : 636 - 638
[26] FDA ARTHRITIS ADVISORY-COMMITTEE MEETING - POSTMARKETING SURVEILLANCE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS
PAULUS, HE
ARTHRITIS AND RHEUMATISM, 1985, 28 (10): : 1168 - 1169
[27] FDA Oversight of Postmarketing Studies
Kashoki, Mwango
Lee, Cathryn
Stein, Peter
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12): : 1201 - 1202
[28] Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance
Muraro, Paolo A.
Scolding, Neil J.
Fox, Robert J.
NEUROLOGY, 2018, 90 (18) : 819 - 820
[29] Postmarketing surveillance is needed
Srinivas, VR
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7456): : 51 - 51
[30] THE RATIONALE FOR A POSTMARKETING SURVEILLANCE
WESTERHOLM, B
HUMAN REPRODUCTION, 1987, 2 (01) : 41 - 44

← 1 2 3 4 5 →